AGIO Agios Pharmaceuticals Earnings and EPS analysis

Relative Growth: Rel. Growth: 46

Relative Strength: Rel. Strength: 29

Relative Valuation: Rel. Valuation: 7

Relative Profitability: Rel. Profitability: 21

EPS in 2026 (TTM): -$7.25

Last Report Period Date: Mar 31, 2026

According to the most recent financial data from March 2026, the current EPS (TTM) is -$7.25. Agios Pharmaceuticals's EPS for 2025 came in at -$7.12, marking a decrease from $11.86 in 2024. For the quarterly period ending on Mar 31, 2026, AGIO's EPS was -$1.69.

AGIO earnings history

Historical annual and quarterly earnings per share (EPS) data for Agios Pharmaceuticals

EPS (TTM)

-$7.25

EPS Growth YoY (Quarterly)

-9%

EPS (Quarterly)

-$1.69

EPS Growth (Quarterly)

8.6%

Agios Pharmaceuticals had an annual EPS of -$7.12, marking a decrease of 160% from $11.86 in 2024. The quarterly EPS for the period ending Mar 31, 2026, was -$1.69, marking a 9% decrease from the same quarter last year. AGIO's TTM EPS stands at -$7.25 as of March 2026. Agios Pharmaceuticals's EPS for 2024 stood at $11.86, a 287.4% increase from 2023.

AGIO earnings chart

AGIO EPS growth history

Earnings per share growth rates over time

EPS Growth YoY (Quarterly)

-9%

EPS growth YoY

-160%

EPS growth 3Y avg

N/A

EPS growth 5Y avg

N/A

Over the last 12 months, Agios Pharmaceuticals has registered an EPS growth of -9% (YoY, quarterly).

AGIO Earnings Waterfall

Breakdown of revenue, profit and net income for Agios Pharmaceuticals

AGIO Earnings vs Peers

What are the earnings of AGIO compared to its peers

Stock name	Price to Earnings	EPS grwoth 1Y	EPS grwoth 3Y	EPS grwoth 5Y
EXEL Exelixis Inc	16.88	60%	71.6%	51.6%
PFE Pfizer Inc	19.63	-3.5%	-37.4%	-3.7%
LLY ELI LILLY & Co	39.92	95.6%	49.2%	27.5%
BMRN Biomarin Pharmaceutical Inc	40.61	-19.1%	33.8%	-17.4%
XNCR Xencor Inc	N/A	65.4%	N/A	N/A
AGIO Agios Pharmaceuticals Inc	N/A	-160%	N/A	N/A

All data is based on quarterly TTM periods, unless otherwise specified.